Open Call For Digital Health Innovation!

DayOne Accelerator supports digital health entrepreneurs and their innovative projects. This year the themes are diabetes and metabolism, value-based healthcare, and patient-centric innovation.

 

DayOne Accelerator program helps digital projects tackle challenges in healthcare innovation. If you are a digital health entrepreneur, this article might be of interest because, with DayOne Accelerator, you can gain feedback on your innovation project and build connections in the healthcare ecosystem. This accelerator is an excellent opportunity for innovative ventures solving problems across a broad range of healthcare areas in digital health. DayOne helps promising ventures combining ground-breaking technologies, healthcare expertise, and entrepreneurial spirit. Furthermore, this program supports innovative healthcare ventures to build the team, skills, and connections necessary to assured success.

This accelerator is aimed not only at start-ups but also at innovators from across the range of patients and doctors’ entrepreneurs to corporate intrapreneurs. DayOne is looking for innovation in the early stages, for instance, idea stage or proof of concept, but will also consider later stage ventures. Ventures are selected on their promise and ability to meet the challenges requested by DayOne partners. As we mentioned before, the specific themes considered for this year are:

  • Diabetes & Metabolism: projects will get access to specialized partners, services, and potential funding, provided by Diabetes Centre Berne.
  • Value-Based Healthcare: projects will be supported by a consortium with representatives from the Provider, Pharma, Payer, Data, and Entrepreneurial community. Ventures applying in this specific theme will have the opportunity to apply for up to CHF 30k in project funding to work with the consortium partners.
  • Patient-Centric Innovation: the Health Hack consortium will support the projects. Ventures can apply without having participated in the Health Hack.

 

What do I need to do to enrol?

The first step in the accelerator process is participating in the DayOne Open Innovation Session, which is part of the DayOne Conference taking place this year on the 12th of November. Participants of this Open Innovation Session can then apply to the accelerator. Enrol before the 23rd of October, and don’t miss out on this great opportunity!

By the 5th of November, the DayOne team will let you know if you are shortlisted for the accelerator program and therefore invited to DayOne Open Innovation Session.

The Accelerator program will start in January 2021, and winners will receive:

  • Access to one of Europe’s leading healthcare ecosystems
  • 6 months of tailored coaching and workshops
  • Regulatory, legal, and other applicable services
  • Access to customers
  • Possible funding from the partners
  • A desk at the collaborative space Switzerland Innovation Park Basel Area Novartis Campus
  • Selected applicants of the accelerator will also get the opportunity to get direct feedback from a panel of providers and technology experts at the University Hospital Basel and University Children’s Hospital Basel (UKBB).

 

Link to enrol to the DayOne Open Innovation Session here.

 

About DayOne

DayOne, initiated by a Core Team of volunteering industry experts, medical doctors, tech enthusiasts, and researchers, serves a growing community of 2000 healthcare innovators throughout the Basel life sciences and healthcare ecosystem. DayOne is operated by BaselArea.swiss, the office for promoting innovation and inward investment for the cantons of Basel-Stadt, Basel-Landschaft, and Jura. DayOne is supported with a unique financial contribution by the canton of Basel-Stadt and also by a wide range of knowledge partners and supporting partners.

 

About Hemex

HEMEX is a private investment and consulting company headquartered close to the Basel global life sciences hub. Our primary focus is to bring innovative drugs, medical devices, and in-vitro diagnostics to the market. We specialized in supporting early-stage start-ups, offering tailored solutions to accelerate projects into successful and sustainable businesses. We firmly believe in AMT Medical’s project, and we support them in diverse areas providing expertise. If you would like to know more about our work, you can find more information at HEMEX.

Startup DAYs: A Unique Platform To Networking

Hemex attended the Startup DAYs 2020, and we are delighted to have seen all the brilliant ideas presented. There is a bright future for swiss innovation!

 

Since 2003, the Startup DAYs event is among the best opportunities in Switzerland to grow your network, learn from top experts, and meet potential partners, supporters, corporates, and investors. Despite COVID-19, this year the event was held in Bern on Monday and Tuesday, and the HEMEX’s team had the opportunity to witness the perfect organization. To respect the social distancing rules at all times during the event, the number of on-site participants was limited to a maximum of 650 people per day, and the use of masks was mandatory. Moreover, this year the option to purchase an online ticket was available to everyone who wished to participate, and all interactions on the main stage were live-streamed to the virtual participants. 

 

The Startup DAYs fosters collaboration among the startup ecosystem, and we would like to quickly explain why HEMEX thinks you should register for next year. If you attend the Startup DAYs, you have the opportunity to:

  • Learn from masterclasses, workshops, Q&A sessions, and Keynotes&Pannels
  • Discover the best Deep Technology available from the most promising startups from Switzerland.
  • Connect with the most promising startup and scale-up founders, investors, corporates, and support organizations.

This event it’s a great opportunity for anybody who’d like to build on their network in the Start-up environment. At HEMEX, we believe in accelerating innovation by connecting people, that is why we are delighted that we connected and met remarkable minds this year. 

A big congratulations to all Startups that pitched, the Pitching Battles were very exciting! This year they were also live-streamed to virtual participants to ensure properly complying of safety regulations. We are looking forward to seeing the future innovative projects these brilliant minds are going to create. As we mentioned, the organization of the event was superb. The HEMEX’s team is very thankful to the Startup INVEST, who, yet another year, did an outstanding job. 

 

About Startup DAYs

GAME CHANGERS & CHANGE MAKERS.

The startup DAYs is the reference event in Switzerland to discover and engage about innovation. Startup INVEST organizes this anual event that offers a fantastic platform to decision-makers, startups, investors and corporates from all over the world to exchange ideas through meetings and networking.

 

 

About Hemex

HEMEX is a private investment and consulting company headquartered close to the Basel global life sciences hub. Our primary focus is to bring innovative drugs, medical devices, and in-vitro diagnostics to the market. We specialized in supporting early-stage start-ups, offering tailored solutions to accelerate projects into successful and sustainable businesses. We firmly believe in AMT Medical’s project, and we support them in diverse areas providing expertise. If you would like to know more about our work, you can find more information at HEMEX.

Registration open for de Vigier Award 2021

The W.A. de Vigier Award 2021 opens the registration period on the 1st of October. Start today to prepare your application for being part of one of the most prestigious awards in Switzerland!

 

The purpose of the W.A. de Vigier Foundation has been, since it’s foundation in 1987, to strongly stimulate business development and offer financial support to innovative ideas lead by committed entrepreneurs who would like to create growth-oriented businesses in Switzerland.

The foundation has allocated over CHF 11 million seed capital over the past 31 years. The great track record of the start-ups participating in the W.A. de Vigier Award is notable on their results; 90 motor-driven start-ups, successful IPOs, multiple company exits, and above all, many newly created jobs. The W.A. de Vigier foundation stone is their creative spirit and dedication to promote entrepreneurial innovation.

For next year’s award, the application period is starting on October 1, 2020, until January 4, 2021. Here are the most important points you should take into account if you are planning to register:

Who can participate?

The CEO of the company must apply and go through the entire process personally. All entrepreneurs need to:

  • be able to present an innovative, future-oriented product or service concept
  • be dedicated to their project full time
  • have already or are about to establish a Switzerland-based company
  • have their registered residence in Switzerland
  • are (usually) not older than 45 years

2. What are the criteria? 

The assessments evaluated are:

  • Founder and entrepreneur profile
  • Innovative character
  • Overall relevance in society; the degree to which it satisfies an existing need
  • Feasibility of the project’s realization from a
    • technical standpoint
    • financial standpoint
  • Chances of success on the market
    • size of the potential market
    • number of jobs created
  • Market competitiveness

 

The W.A. de Vigier Award is the oldest and highest endowed prize for start-ups and young entrepreneurs in Switzerland. With the annual prize money of CHF 500,000 (five equal prizes at CHF 100,000 each), these awards rank among the most highly endowed start-up prizes in Switzerland. If you would like to know a little more about W.A. De Vigier Foundation, click HERE

If you are looking for funding and visibility, don’t miss this opportunity! Complete and submit your application BEFORE 04.01.2021. Do you need help with the registration? Are you having trouble finding your seed financing? At HEMEX, we can help you find and get non-dilutive grants like this and many others; contact us at yaozi.moreno@hemex.ch

We are very proud of our portfolio companies that have been part of the W.A. De Vigier Foundation award in the last two years. Last year Annaida, LiVET and Juvabis were in the Top16! Moreover, two years ago Sleepiz won a 50’000 CHF prize  at the 30th anniversary edition of the W. A. De Vigier Foundation! 

 

If you would like to register directly; HERE.

 

About Hemex

HEMEX is a private investment and consulting company headquartered close to the Basel global life sciences hub. Our primary focus is to bring innovative drugs, medical devices, and in-vitro diagnostics to the market. We specialized in supporting early-stage start-ups, offering tailored solutions to accelerate projects into successful and sustainable businesses. We firmly believe in AMT Medical’s project, and we support them in diverse areas providing expertise. If you would like to know more about our work, you can find more information at HEMEX.

Who are the Top 100 Swiss Start-ups in 2020?

The Top 100 Swiss Start-up celebrated a very special edition yesterday. Besides being their 10th anniversary edition, for the first time, the award show was live-streamed for safety reasons, and ran perfectly smoothly!

 

At Hemex, we are very proud of our five portfolio start-ups that have made it onto the Top 100 Swiss Start-up. For a Start-up to get onto this list is a big honour because they are selected by a panel of 100 leading investors and experts. Keep an eye on them this year because they are going to be in the spotlight of innovation! 

Firstly, we would like to congratulate ASPIVIX and Scailyte for being in the top 100!

Aspivix is developing the next-generation surgical instrument for gentle and modern gynaecological procedures. Aspivix’s device is a gentle vacuum suction-pad applied to the cervix to steady it during gynaecological procedures. Pain is minimized, there is no bleeding, the risk of cross-contamination is eliminated, and the whole experience is less traumatic.

 

Scailyte logo

Scailyte is a data-driven biomarker discovery company that detects complex disease patterns from single-cell data at the onset of disease. Scailyte’s technology provides unprecedented insights into diseases by uncovering hidden “single-cell” secrets. With an AI-driven approach, Scailyte is unlocking the potential of single-cell data for early diagnostics. 

 

Secondly, we would like to congratulate Annaida Technologies for being in the top 50! Annaida was also second in the Top 3 best Newcomers for the Top 100 Start-up’s 2020.

Annaida Technologies logo

Annaida Technologies is the first high-tech company start-up bringing magnetic resonance to embryo scale. Annaida is an EPFL spin-off that is harnessing a technology that is delicate enough to use on a human embryo. The start-up’s device performs microscopic Nuclear Magnetic Resonance (“µNMR”) at a scale 10-fold better than existing technologies. 

 

Thirdly, huge congratulations to our portfolio company Resistell AG for being in the top 10! Resistell was also in the top 3 best Biotech start-ups.

Resistell logo

Resistell is a EPFL spin-off that has been able to successfully achieve reliable antibiotic susceptibility results up to 100 times faster than conventional, culture-based methods. Resistell’s test is based on the measurement of living bacteria vibrations from the sample by using nanosensors. This reduces the time-to-result from several hours or days to less than two hours. Patients can be treated with optimal medication from day one. 

 

TOP 100 Swiss Start-ups ranking brings the best investors together with the best start-ups. It’s the most prestigious start-up award in Switzerland. Being among the TOP 10 is a huge recognition and was definitely unexpected, especially given that we were incorporated only two years ago. For Resistell it’s a huge motivation to work even harder now to climb up the list next year!                                                                                                   – Danuta Cichocka, CEO of Resistell. 

 

Finally, a special mention to Sleepiz, who won the public vote for medtech Start-ups!

Sleepiz logoSleepiz has produced innovative technology that will revolutionize the medical community. It is a patient-centered simple device that you can put on your bedside table. Their advanced equipment operates without cables and captures vital signs without touching the patient. With advanced statistical models and artificial intelligence, the device provides accurate analysis and insights to diagnose sleep disorders at home. 

 

As we mentioned before, for a Start-up to get onto this list is a big honour.The jury are all specialists in the start-up sector and chooses the 100 start-ups with the most significant potential in Switzerland. This is how it works; each expert chooses ten start-ups and ranks them from one to ten.  Subsequently, the start-ups with the highest scores are the ones that made it onto the list.

Top 100 Swiss Start-up Award brings the most innovative Swiss Start-ups into the public eye. This award is not only for Swiss Start-ups but also international companies. In the 10th anniversary edition, the first three positions went to Cutiss (1st), Wingtra (2nd), and Piavita (3rd). Additionally, the Public Voting award went to Acatena. At Hemex we wanted to contratulate these four start-ups, we believe they have a very promising and ground-breaking future. Therefore, we suggest you also keep an eye on them as well!

 

 About Hemex

Hemex is a private investment and consulting company headquartered close to the Basel global life sciences hub. Our primary focus is to bring innovative drugs, medical devices, and in-vitro diagnostics to the market. We specialized in supporting early-stage start-ups, offering tailored solutions to accelerate projects into successful and sustainable businesses. If you would like to know more about our work, you can find more information at HEMEX.

The next step in heart bypass technology

About 1,000,000 patients undergo highly invasive heart bypass surgery yearly. Our portfolio company AMT Medical has developed a unique technology to enable a safe, affordable, and minimally invasive coronary bypass surgery.

 

Every single day, millions of people suffer from Coronary Artery Disease (CAD). As the name suggests, it is a disease of coronary arteries, where usually these arteries get completely or partially blocked due to cholesterol deposits. CAD is the most common type of heart disease, and it is the leading cause of death in many countries of the world. This disease can have long and stable periods but might also become unstable at any time. CAD is a serious progressive and chronic disease that needs to be controlled and checked periodically.

In severe cases, Coronary Artery Bypass Graft (CABG) might be needed. CABG is a surgical procedure used to treat CAD. Coronary Artery Bypass Graft is performed when there is a blocked artery in the heart, or in emergency situations, such as heart attack if there is no response to other treatments. This procedure is highly invasive and is associated with long recovery times and serious complications, mainly due to the opening of the chest and stopping the beating of the heart during the surgery; these conditions could lead to complications during or after the surgery. 

AMT Medical is developing a unique coronary bypass system based on a technique used for similar indications in the brain. ELANA (Excimer Laser-Assisted Non-Occlusive Anastomosis), the sister company from AMT, introduced this procedure to the market for neurosurgery. Now AMT it’s applying it for CABG. ELANA enables a safe, affordable, and easy-to-use minimally invasive Coronary Artery Bypass Graft securing shorter recovery time and fewer complications. 

The AMT technique enables ELANA Coronary Bypass to be performed through small holes in the chest. Therefore the need to open the chest is not necessary anymore; neither is the heart-lung machine nor the suturing to hold the graft in place. For the patient, this means fewer chances of infections, internal bleeding, stroke, and much shorter recovery time. 

The European Commission awarded last year a consortium led by AMT Medical, including HEMEX, with a €2.2 M grant under its “Fast-Track to Innovation (FTI)” program. Under this proposal, HEMEX is in charge of planning, coordinating, and executing the multicentric, pan-European study in order to obtain the CE-mark for the Excimer Laser-Assisted Non-Occlusive Anastomosis (ELANA) Heart Bypass System in Patients undergoing Coronary Artery Bypass Grafts (CABG).

For more information on the progress of this life-changing therapy, please contact franziska.stemmler@hemex.ch

Co-funded by the Horizon 2020 Framework Programme of the European Union and the Grant Agreement (GA) No. 869922. 

About AMT Medical

AMT Medical is a pre-clinical stage medical device company from the Netherlands. Together with the UMC Utrecht is developing a unique coronary bypass system. AMT’s motivation is to develop simple ‘best in class’ coronary bypass technology through keyholes. The new standard, with lower costs for society, fewer complications, and a faster recovery for the patient.

 About Hemex

Hemex is a private investment and consulting company headquartered close to the Basel global life sciences hub. Our primary focus is to bring innovative drugs, medical devices, and in-vitro diagnostics to the market. We specialized in supporting early-stage start-ups, offering tailored solutions to accelerate projects into successful and sustainable businesses. We firmly believe in AMT Medical’s project, and we support them in diverse areas providing expertise. If you would like to know more about our work, you can find more information at HEMEX.

Swisscom StartUp Challenge – Pitch your 5G Case and Win!

This year, the program is aimed at start-ups and research teams whose solutions are based around the latest 5G mobile generation.

 

What is this year’s theme?

After seven successful editions, this year’s Swisscom StartUp Challenge has a unique theme for the first time and has taken on an international dimension. The program is aimed at start-ups or research teams whose solutions are based on the latest 5G mobile generation. It provides a unique chance for tech start-ups and research teams to pitch their products or functioning prototypes to an expert jury and win a weeklong Exploration Programme in Switzerland with a 5G innovator.

Who can participate?          

– Tech start-ups with a clear competitive edge that are ready to enter or have already entered the market.

– Research projects relating to 5G applications based, for example, at universities and other higher           education institutions. 

What can the ten finalists expect?

  • Participation in the pitch event on 17 December 2020 at the Swisscom Pirates Hub Zurich or via telepresence
  • Pitch training with personal feedback from venturelab experts to help prepare for the final on 3 December 2020
  • Analysis of business cooperation with Swisscom and investment by Swisscom Ventures
  • Easy access to the Swisscom and programme partner networks (Venturelab, Ericsson, Qualcomm)
  • Visibility thanks to inclusion in publicity surrounding the Swisscom StartUp Challenge

What can the five winners expect?

  • Working with the latest 5G architectures where E2E testing can take place
  • Access to the Swisscom 5G network at a range of locations 
  • Access to 5G smartphones, hotspots, tablets, laptops, existing Swisscom services, and testing tools
  • Support/mentoring by 5G experts from Swisscom and partner firms/program partners
  • Further development of marketing and sales skills
  • An unforgettable week in Switzerland including a visit to the Swiss Federal Institute of Technology and Swiss business/technology innovators

Where to apply?

Let’s shape the future together with the Swisscom StartUp Challenge! Apply with your 5G use case before 11 October HERE.

For general questions, contact Jennifer Adam (jennifer.adam@swisscom.com)

 

About the Swisscom StartUp Challenge

The Swisscom StartUp Challenge was launched in 2013. To date, they have been able to accompany numerous start-ups on their journey. They believe in the innovative strength of start-ups, and this year they are supporting 5G-related research projects. More at Swisscom.

 

About Hemex

HEMEX AG is a privately-owned Swiss investment and consulting company headquartered close to the Basel global life sciences hub. Its primary focus is to bring innovative drugs, medical devices, and in–vitro diagnostics to the market. HEMEX specializes in supporting early-stage start-ups, offering tailored solutions to accelerate projects into successful and sustainable businesses. Additionally, HEMEX helps and supports start-ups to find non-dilutive and dilutive funding. More at HEMEX.

Swiss Innovation Challenge – 2nd Round Pitches!

Outstanding swiss and international start-ups and SME’s presented yesterday their business projects at the 2nd round of the Swiss Innovation Challenge.  

 

The Swiss Innovation Challenge (SIC) is an innovation promotion program in which 25 finalists and one winner are selected from over 100 innovation projects in three elimination rounds. The participants in the competition are SMEs and start-ups from around the globe. SIC offers attractive awards and a unique 8-month acceleration program. Furthermore, it helps participants to build a concrete path towards recognition and business success. They benefit from individual coaching, tailored education, and extensive mentoring. This is a very important point for the participants, as they can get easier access to sponsors and potential business partners.

Over the last two days, the second pitch of SIC 2020 has taken place at the University of Applied Sciences and Arts Northwestern Switzerland. The 50 selected participants from the last round have presented their innovative projects in front of a very experienced jury. This second round has been very successful. Following safety guidelines to help prevent the spread of COVID-19, all participants and the jury wore face masks. The contestants presented (online and on-site) their projects with great enthusiasm to the jury.  

In this 6th edition, Hemex is supporting this Challenge with a special prize in the “Life Sciences” category. We were also very honored to be part of the jury for the first time. The participants’ devotion to their projects motivates us to continue working in the development of innovative solutions for the healthcare industry. Overall, 25 ventures will make it to the next stage and pitch in the 3rd round of this challenge. We would like to wish all start-ups the very best of luck! The award ceremony will take place in November.

 

About Hemex

HEMEX AG is a privately-owned Swiss investment and consulting company headquartered close to the Basel global life sciences hub. Its primary focus is to bring innovative drugs, medical devices, and in–vitro diagnostics to the market. HEMEX specializes in supporting early-stage start-ups, offering tailored solutions to accelerate projects into successful and sustainable businesses. Additionally, HEMEX helps and supports start-ups to find non-dilutive and dilutive funding. More at HEMEX.

Interview with Scailyte’s CEO Peter Nestorov

In an interview on the platform for high-tech startups Venturelab, Peter confirms something that we were already starting to presume in Hemex; Scailyte is developing rapidly. “However, the learning curve has been and still is extremely steep – as the start-up develops rapidly, so do I, and that is really exciting”.

As a founder and CEO, Peter faces a lot of challenges in his daily activities, but he always had the interest to be involved in multiple initiatives. “I managed a student NGO during my studies and organized numerous international meetings, so I had some basis when I decided to become the CEO of a startup”. It is exactly this transition to become the CEO of a company like Scailyte that has given Peter the skills to succeed as an entrepreneur.

The path of an entrepreneur is sometimes harsh. Peter states that surrounding yourself with a smart and experienced team is necessary. “What helps me a lot is the support and coaching I receive from more experienced entrepreneurs and experts from various industries”.

We at Hemex are thrilled to work with vibrant start-ups like Scailyte. Our slogan “Your Ideas. Our Expertise. One Goal.” reflects that we support the start-ups to achieve a common goal, to efficiently combine the smart ideas of entrepreneurs like Peter Nestorov, with our bench-to-market expertise in order to improve patients’ lives.

You can find the full interview here.

Scailyte is a data-driven biomarker discovery company, that detects complex disease patterns from single-cell data at the onset of disease. Only a small fraction of cells is abnormal, and the changes of the molecular profile are subtle. Scailyte’s technology provides unprecedented insights into diseases by uncovering hidden “single-cell” secrets. With an AI-driven approach, Scailyte is unlocking the potential of single-cell data for early diagnostics. Scailyte is ranked among the Top100 Swiss Startups since 2019 and has won the MassChallenge Switzerland in 2018.

Hemex is a privately-owned Swiss investment and consulting company headquartered close to the Basel global life sciences hub, with its focus to bring innovative drugs, medical devices, and in vitro diagnostics to the market. HEMEX specializes in supporting early-stage start-ups, offering tailored solutions to accelerate the project into a successful and sustainable business. Additionally, HEMEX helps start-ups in their efforts to find non-dilutive and dilutive funding.

At Hemex we are proud to have recognized Scailyte’s potential and to be part of their successful journey.

Scailyte is finalist for Nature Research Spinoff Prize!

Congratulations to our portfolio company Scailyte for being selected among the 12 finalists for the Nature Research Spinoff Prize.

The Spinoff Prize is a new Nature Research Award for early-stage university spinoff companies from around the world. The Award has been established by Nature Research in partnership with Merck to showcase and celebrate global excellence in the commercialization of research through the creation of spinoff companies. The Spinoff Prize aims to encourage and provide visibility to academic entrepreneurs and their startups. The judging panel looks for spinoffs that translate original, high-quality scientific research into products and services that address market problems and are well positioned to make a positive impact on society. The focus of this year’s award involves four categories: pharmaceuticals, agriculture, chemicals, and digital technologies. We are particularly proud that Scailyte has reached the finals of this fantastic showcase!

Scailyte is a data-driven biomarker discovery company, that detects complex disease patterns from single-cell data at the onset of disease. Only a small fraction of cells is abnormal, and the changes of the molecular profile are subtle. Scailyte’s technology provides unprecedented insights into diseases by uncovering hidden “single-cell” secrets. With an AI-driven approach, Scailyte is unlocking the potential of single-cell data for early diagnostics. Scailyte is ranked among the Top100 Swiss Startups since 2019 and has won the MassChallenge Switzerland in 2018.

Hemex is a privately-owned swiss investment and consulting company headquartered close to the Basel global life sciences hub, with its focus to bring innovative drugs, medical devices, and in vitro diagnostics to the market. HEMEX specializes in supporting early-stage start-ups, offering tailored solutions to accelerate the project into a successful and sustainable business. Additionally, HEMEX helps start-ups in their efforts to find non-dilutive and dilutive funding.

At Hemex we are proud to have recognized Scailyte’s potential and to be part of their successful journey.

Swiss Innovation Challenge – 2nd Round!

Numerous Swiss and European start-ups and SME’s applied for this year’s Swiss Innovation Challenge! In the 1st pitching round, 100 innovative participants presented their projects in front of a competent jury.  Selected start-ups also benefit from a comprehensive support platform with individual coaching, tailored education, and mentoring, as well as get access to potential investors and business partners.

Next, 50 ventures move on to the 2nd pitching round in this challenge. Start-ups and SMEs continue to receive expert support to accelerate their innovative projects and face the competition through three elimination rounds in total. In addition to the main award, participants can win special prizes in the fields of “Globalization”, “Life Sciences” and “Construction”.

Within the Life Sciences Start-ups, we are proud to see 3 HEMEX portfolio start-ups!

 

GeneLook logoGeneLook enables patients to actively use their genetic data in a meaningful way by allowing the healthcare ecosystem to utilize their data in order to facilitate discoveries of new treatments. GeneLook strategically focuses on rare disease patients, to further characterize their diseases, and to improve and accelerate the medical treatment journey.

 

Hi-D Imaging logo

Hi-D Imaging is an ETHZ spin-off aiming to revolutionize the cardiovascular sector by making personalized heart valve replacement therapy a reality. Hi-D (pronounced “Heidi”) develops the world’s first AI-based pre-operational planning platform to assess different heart valves for the patient-specific anatomy, and recommends the optimum shape and size of the valve to the surgeon. The start-up’s technology will increase the quality-of-life of the patient, decrease complications, reduce long-term costs, and increase the overall success rate of the surgery.

 

Resistell logoResistell is an EPFL spin-off developing world’s fastest antibiotic susceptibility test in order to help physicians around the world save patients’ lives. Resistell’s solution is needed more than ever due to increasing antimicrobial resistance, emergency of side effects due to potent antibiotics, not the least in the context of global pandemics. Its life-saving technology is based on the detection of movement caused by living bacterial cells and provides information on which antibiotic should be used to treat the patient, and the concentration at which it should be administered

 

HEMEX is a Bench-to-Market Life Science Provider. We support life science start-ups with a wide range of expertise, either in-house or via our network of pre-qualified experts, laboratories, CMOs, warehouses, logistic partners and affiliates. Our development team supports with Quality Assurance, Medical and Regulatory Affairs, Clinical Operations, Biostatistics, Medical Writing and eSubmissions.